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Abstract
The chemotherapeutic drug epirubicin increases the exosomal export of miR-503 in endothelial cells. To understand the 
mechanisms behind this process, we transfected endothelial cells with miR-503 carrying a biotin tag. Then, we pulled-down 
the proteins interacting with miR-503 and studied their role in microRNA exosomal export. A total of four different binding 
partners were identified by mass spectrometry and validated by western blotting and negative controls, among them ANXA2 
and hnRNPA2B1. Using knock-down systems combined with pull-down analysis, we determined that epirubicin mediates 
the export of miR-503 by disrupting the interaction between hnRNPA2B1 and miR-503. Then, both ANXA2 and miR-503 
are sorted into exosomes while hnRNPA2B1 is relocated into the nucleus. The combination of these processes culminates in 
the increased export of miR-503. These results suggest, for the first time, that RNA-binding proteins can negatively regulate 
the exosomal sorting of microRNAs.
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Abbreviations
Epi  Epirubicin
EVs  Extracellular vesicles
HUVECs  Human umbilical vein endothelial cells
HMVECs  Human microvascular endothelial cells
ANXA2  Annexin A2
hnRNPA2B1  Heteronuclear ribonucleoprotein A2/B1




MEC  MicroRNA exporting complex
Introduction
Exosomes are small bilipidic vesicles ranging in size 
between 30 and 150 nm [1] produced in the endosomal 
compartment of virtually all cells. These vesicles medi-
ate extracellular communication through the exchange of 
information via receptor signaling and/or by absorption, via 
either endocytic processes or pinocytosis/phagocytosis [2]. 
The content of exosomes is dictated by the parent cell type, 
as well as by the status and the environment of the cells 
at the time of production [3]. Even though exosomes may 
carry different cargo (coding and non-coding RNA [4], DNA 
[5], lipids [6] and proteins [7]), multiple studies have shown 
that the loading of specific RNAs (in disease) can promote 
phenotypic changes in the recipient cells [8].
MicroRNAs are small non-coding RNAs involved in the 
negative regulation of gene expression. Although changes 
in the exosomal RNA profiles often reflect changes in the 
parental cells, cellular stimulus can also modify the encap-
sulation of specific microRNAs. An example of this mecha-
nism is the anti-tumoral microRNA miR-503. Our group 
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previously reported that breast cancer patients receiving the 
neoadjuvant epirubicin had increased circulating levels of 
miR-503. We then demonstrated that this chemotherapeutic 
drug could promote, in endothelial cells, the production of 
exosomes with anti-tumoral properties loaded with miR-503 
[9]. In conclusion, we highlighted an exosome-dependent 
transfer of microRNAs from endothelial to tumor cells that 
contributes to the anti-tumoral effect of epirubicin. Our 
data suggested the presence of an underlying mechanism 
leading to the selective export of miR-503 in endothelial 
cells. To date, several studies have focused on motif-based 
RNA-binding protein (RBP) recognition to explain exo-
somal microRNA export, but the mechanisms behind this 
process still remain mostly unknown. In this study, combin-
ing microRNA pull-down techniques along with proteomic 
assays and knock-down studies, we discovered that epiru-
bicin promotes the exosomal export of miR-503 by desta-
bilizing the interaction between this microRNA and hnRN-




Human umbilical vein endothelial cells were isolated as 
previously described by [10]). HUVECs were amplified in 
flasks coated with gelatin (0.2%) in endothelial cell growth 
media-2 (EGM2) (Lonza, Germany) lacking heparin and 
supplemented with 5% donor bovine serum (DBS) at 
37 °C and 5%  CO2. Human microvascular endothelial cells 
(HMVECs) (Lonza, Germany) were cultured in EGM2 lack-
ing heparin and supplemented with 5% fetal bovine serum 
(FBS) at 37 °C and 5%  CO2. All exosomes experiments were 
performed in exosome-depleted media prepared using serum 
that had been centrifuged at 110,000g for 16 h at 4 °C to 
reduce exosomal contamination (Beckman Coulter Optima 
L-90K, SW32 Rotor). Cells were stored in liquid nitrogen for 
further use and used for experimental procedures from pas-
sage 6 (P6) to P10. The concentration of epirubicin used in 
all experiments was 1 µg/ml in complete EGM2. The levels 
used for this test were decided after calculating the circulat-
ing concentration of this drug in patients [9].
Exosome purification and characterization
HUVECs and HMVECs were cultured in heparin-free 
EGM2 supplemented with full 5% DBS (v/v) or exosome-
depleted DBS. Cells were incubated at 37 °C and 5%  CO2 
up to P10 at a seeding density of 1.8 × 106 cells per 175 cm2 
flask. 3 days later, the supernatant was recovered, and 
exosomes were purified by sequential ultracentrifugation. 
The media were first centrifuged at 2000g for 20 min at 
4 °C to remove unattached cells, followed by a second round 
of centrifugation at 12,000g (45 min at 4 °C) to remove 
cell debris and larger vesicles. The supernatant was then 
collected and passed through a 0.2 μm filter and ultracen-
trifuged at 110,000g for 2 h at 4 °C to pellet the exosomes 
(Beckman Coulter Opitima L-90K, SW32 rotor). The pellet 
was washed with PBS to remove any possible coprecipitated 
protein complexes, and with a final round of centrifugation at 
110,000g for 2 h at 4 °C, the pellet was recovered and stored 
in PBS at − 80 °C. Exosomes were characterized by dynamic 
light scattering (DLS) for vesicle size and by western blot-
ting for protein composition. In brief, the protein characteri-
zation of cells and exosomes was performed following the 
MISEV 2018 guidelines [11] using the following antibodies: 
CD63 (#10628D, Invitrogen), CD9 (#sc20048, Santa Cruz), 
CD81 (#10630D, Invitrogen), SYN (#ab133267, Abcam), 
and cytochrome c (#556433, BD Pharmingen) for immune 
detection.
Electron microscopy of whole‑mounted 
immuno‑labelled exosomes
Isolated exosomes were placed on Formvar/carbon coated 
nickel grids for 1 h, washed three times with PBS and fixed 
with 2% paraformaldehyde for 10 min. After three washes, 
grids were then incubated for 2 h with the following anti-
bodies: anti-CD63 (#H5C6, BD Phamingen) or anti-CD105 
(#M3527, DAKO). Exosomes were then washed five times 
and incubated with a 10 nm-gold labeled secondary anti-
body. They were washed five more times and post-fixed 
with 2.5% glutaraldehyde for 10 min. Samples were con-
trasted using 2.5% uranyl acetate for 10 min followed by 
four washes and an incubation of 10 min in lead citrate. 
Grids were finally washed four times in deionized water 
and examined with a JEOL JEM-1400 transmission electron 
microscope at 80 kV.
Design of the synthetic microRNA
The microRNA mimics miR-503-biotin and cel-miR-67-bi-
otin are double-stranded RNAs designed following the pub-
lications by Orom and Lund [12] and Betancur et al. [13]. 
In summary, the mature microRNA strand was modified by 
the addition of a biotin to the 3′ –OH and a phosphoryla-
tion at the 5′ end. The carrier strand (miR-503-reverse or 
cel-miR-67 reverse) was the complementary RNA sequence, 
which was also phosphorylated at the 5′ end and carried a 
two bases 3′ overhang with mutations near the 3′ end to 
thermodynamically destabilize the strand and induce faster 
degradation. Supplementary Fig S1 shows the sequence and 
modifications induced in the microRNA duplexes. Oligonu-
cleotides were purchased from Eurogentec.
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Preparation of protein lysates and western blotting
HUVECs were washed with PBS 1 × and RIPA buffer was 
added (50 mM Tris pH 7.5, 150 mM NaCl, 10 mM  CaCl2, 
0.5% NP40, 0.25% sodium deoxycholate and 0.1% SDS) at 
75 µl/106 cells. The plates/flasks were then scratched and 
the cellular lysate was centrifuged at 10,000g and 4 °C for 
15 min. The cleared supernatant was then recovered and 
the pellet (cellular debris) discarded. The quantification of 
cellular lysates was performed using the BCA Protein Assay 
Kit (Pierce) following the manufacturer’s instructions. For 
exosomes, the lysis of the samples was performed using 
exosome lysis buffer (10% Triton, 1% SDS) and the quanti-
fication of exosomal protein was performed with BCA Pro-
tein Assay Kit (Pierce) incubating the samples at 60 °C for 
60 min. Prior gel loading, samples were denatured by boil-
ing at 95 °C for 7 min in 1 × loading buffer (40% Glycerol, 
240 mM Tris/HCl pH 6.8, 8% SDS, 0.025% Bromophenol 
Blue) without 5% β-mercaptoethanol for the detection of 
tetraspanins (CD9, CD63, and CD81) and with the reducing 
agent for all the other proteins. Equal amounts of protein 
lysates (10 µg) were electrophoresed on a 12% SDS–poly-
acrylamide gels and transferred to a polyvinylidene fluoride 
membrane using a wet transfer system. The blots were then 
blocked with either 5% BSA (in the case of hnRNPA2B1) 
or commercial powdered milk at 8% for 1 h. Blots were 
then incubated overnight at 4 °C with the primary anti-
body [ANXA2 (#8235, Cell Signaling), FN1 (#610077, 
BD Phamingen), HNRNPA2B1 (#Ab6102, Abcam), TSP1 
(#MA5-13398, Thermo Fisher), VIM (#MO72529, DAKO), 
VINC (#Ab129002, Abcam), and SYN (#Ab133267, Abcam)]. 
After three washes of 10 min with TBS/0.1% Tween-20 
(TBST), the membranes were incubated for 1 h at room 
temperature with an HRP-conjugated secondary antibody 
(anti-rabbit (#7074S, Cell Signaling), anti-mouse (#7076S, 
Cell Signaling) and washed twice with TBST and once with 
TBS. The blots were then incubated with enhanced chemi-
luminescence (ECL) substrate (Pierce Biotechnology) and 
exposed to films. All films were scanned and the intensity 
of the bands was quantified using ImageJ.
MiR‑503 and cel‑miR‑67 pull‑down
To detect the proteins associated with miR-503, HUVECs 
or HMVECs were transfected with 10 nM miR-503-biotin 
or cel-miR-67-biotin duplexes at the time of seeding. For 
this purpose, 7.5 µl of DharmaFECT 4 (Dharmacon) were 
mixed with 2242.5 µl of serum-free EBM2 (Lonza) and 
incubated at room temperature for 10 min. After this, a 
second solution containing 2235 µl of EBM2 and 15 µl of 
10 µM miR-503-biotin/reverse was prepared. Both solu-
tions were mixed and incubated at room temperature for 
20 more minutes. In parallel, 1.8 × 106 cells were seeded 
in 10.5 ml of full EGM2 (supplemented with 5% DBS) 
in a 145 cm2 round dish previously coated with gelatine 
0.2%. The transfectant-miRNA solution was then added 
to the cells to achieve a final microRNA concentration of 
10 nM in 15 ml. The next day, the media were replaced 
with 20 ml of fully supplemented EGM2 and 2 days later 
we proceeded to pull down the microRNA and its putative 
partners. Forty plates were used for the identification of 
the miR-503-biotin partners by mass spectrometry (see 
supplementary methods for detailed protocol), and ten 
plates were used for the validation of the results.
The protocol used in the pull down followed the meth-
odology described by Rambout X [14] with some modi-
fications. Two crosslinking steps were performed. First, 
after washing twice with ice-cold PBS, 5 ml of a 1 mM 
3,3-dithiobis(sulfosuccinimidylpropionate) (DTSSP) solu-
tion was added to the plates and incubated for 2 h at 4 °C 
to induce the crosslinking between proteins. The superna-
tant was removed and the cells were incubated with 20 mM 
Tris–HCl pH 7.6 for 30 min to stop the crosslinking reac-
tion. Then, the plates were washed twice with ice-cold 
PBS. In a second crosslinking step, the formation of cova-
lent bonds between proteins and RNA was induced via UV 
irradiation. For that purpose, the cells were set on an ice 
tray and UV-irradiated (0.4 J/cm2 of 365-nm UV light with 
a Stratalinker 2400). Then, 2 ml of pull-down lysis buffer 
1 (20 mM Tris–HCl pH 7.5, 0.5% SDS, 1 mM EDTA), 
200 U/ml RNAse inhibitor (Roche, Sigma-Aldrich), 1 × 
Halt Protease and phosphatase inhibitor cocktail (Thermo 
Scientific) and 1 pill/10 ml of cOmplete Protease Inhibitor 
(Roche, Sigma-Aldrich) was added per plate and the cells 
scratched. The lysate was recovered and passed through a 
needle (22G) 2–3 times to reduce viscosity. At this point, 
an aliquot of the lysate (1%) was recovered and stored 
at − 20 °C as input. Then, 25 µl (per plate) of magnetic 
streptavidin-coated beads (New England BioLabs) was 
added to the lysate and the mix was incubated in soft agi-
tation for 2 h at 4 °C. The beads were then separated using 
a magnet for 30 min and washed with pull-down washing 
buffer 1 (20 mM Tris–HCl pH 7.5, 500 mM LiCl, 0.1% 
SDS, 1 mM EDTA). The beads were then washed again 
with washing buffer 2 (20 mM Tris–HCl pH 7.5, 500 mM 
LiCl, 1 mM EDTA), separated for 20 min and washed 
one last time with washing buffer 3 (20 mM Tris–HCl pH 
7.5, 200 mM LiCl, 1 mM EDTA) followed by magnetic 
separation for 15 min. After all the washes, the beads were 
resuspended again in denaturing 4 × loading buffer and 
boiled for 10 min at 97 °C. Next, the different pulled-down 
components were separated by electrophoresis on a 12% 
SDS–polyacrylamide gel until the loading buffer left the 
gel. The protocol used for the identification of the putative 
partners of miR-503 by mass spectrometry can be found in 
the Supplementary Methods.
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Immunoprecipitation assays and qPCR
To detect the affinity of the identified proteins with miR-503, 
HUVECs or HMVECs were transfected with a synthetic 
miR-503 (10 nM) (identical to the native mature miR-503) 
following the same protocol used for miR-503-biotin trans-
fection. Twenty-four hours after removing the media and 
48 h after transfection, cells were washed twice with ice-
cold PBS and incubated with 1 mM dithiobis (succinimidyl 
propionate) DSP (ThermoFisher) in soft agitation for 2 h 
at 4 °C. Then, the reaction was stopped by removing the 
supernatant, adding 20 mM Tris HCl and incubating at room 
temperature for additional 30 min. After washing twice with 
ice-cold PBS, the plates were set on an ice tray and irra-
diated with UV light to induce RNA–protein crosslinking 
(0.4 J/cm2 of 365-nm UV light with a Stratalinker 2400). 
Then, 25 µl of RIPA buffer was added to the plates and 
these were scratched using a scraper. The lysate was then 
recovered into an Eppendorf tube and incubated on ice for 
15 min. Then, the samples were centrifuged, and the pellet 
(cellular debris) discarded. A preclearing of the samples (to 
reduce non-specific binding of peptides to the beads), was 
performed by adding 50 µl of protein A agarose beads (per 
plate) (Sigma-Aldrich, 11719408001) and incubating the 
sample for 2 h at 4 °C with rotation. After that, the samples 
were centrifuged at 2800 rpm and 4 °C for 3 min to pel-
let the beads. The supernatant was recovered and 5 µl of 
antibody was added per plate used. As a negative control, 
immunoglobulin G (IgG) was used instead of the specific 
antibody during immunoprecipitation. The samples were 
left to incubate and rotate overnight at 4 °C. The following 
day, 50 µl of protein A agarose beads (per plate) was added, 
and the samples were incubated again for 2 h more at 4 °C 
in rotation. Then, the beads were recovered by centrifuga-
tion (3 min at 2800g and 4 °C) and washed three times with 
IP Lysis Buffer (50 nM Hepes pH 7.5; 150 nM NaCl; 1% 
Triton X-100) (lacking protease inhibitors) for 1 h. After 
the final wash, the beads were resuspended in 100 µl of 
PBS and RNA extraction was performed using miRNE-
asy kit (Qiagen) following the manufacturer instructions. 
The antibodies used for immunoprecipitation were ANXA2 
(#610069, BD Pharmingen), FN1 (#610077, BD Pharmin-
gen), HNRNPA2B1 (#Ab6102, Abcam), TSP1 (#MA5-13398, 
Thermo Fisher), VIM (#MO72529, DAKO), and IgG control 
(#31903, Invitrogen). To identify unspecific interactions, 
HUVECs were transfected with 10 nM of cel-miR-67 and 
the same protocol was followed.
Small interfering RNA assays
Small interfering RNAs (siRNAs) were used to knock down 
the levels of expression of anxa2, hnrnpA2B1, tbsh1, and 
vim. A scramble siRNA (a siRNA without targets in the 
human genome) was used as a control in all experiments 
at the same concentration used for the knock down of the 
other proteins. Oligonucleotides were purchased from 
Eurogentec and sequences are shown in the supplementary 
material. The transfection protocol was as follows per mL 
of final volume to transfect: 700 µl of a solution of EGM2 
and cells was combined with 300 µl of a solution contain-
ing the transfectant and siRNA in EBM2. To prepare this 
mixture, 0.5 µl of DharmaFECT 4 (Dharmacon) was mixed 
with 149.5 µl of serum-free EBM2 (for each milliliter) and 
incubated for 10 min at room temperature. Posteriorly, a 
solution containing 149 µl of serum-free EBM2 and 1 µl 
of siRNA at a concentration of 20 µM was mixed with the 
DharmaFECT dilution and incubated again at room tem-
perature for another 20 min. Finally, the cells (700 µl) were 
seeded in a plate or flask previously coated with gelatine, 
and the siRNA-DharmaFECT solution was added. The fol-
lowing day, the supernatant was removed, and full media 
(EGM2) was added to the cells. To validate the efficiency 
of protein knock-down, 100,000 HUVECs were seeded in 
a 6-well plate and transfected with the siRNAs. The plates/
flasks were then scratched, and the cells were either lysed 
with RIPA buffer for further protein analysis or mixed with 
TRIzol for RNA extraction. The time points used for the 
validation were 24, 48, and 72 h for RNA and 48, 72, and 
96 h for proteins. The rationale behind the 24 h delay (for 
protein level assessment) was to allow the normal levels of 
the protein in the cell to naturally decrease and thus more 
reliably observe the effect of the gene knock-down at the 
protein level. For the production of exosomes after protein 
knock-down and treatment with epirubicin, 1.8 × 106 cells 
[for the non-treated conditions (NT)] and 5.5 × 106 cells (for 
cells treated with epirubicin) were seeded in each T175 flask 
and transfected to a final volume of 18 ml following the 
protocol mentioned above. Then, the next day, the super-
natant was fully recovered and replaced with 20 ml of full 
EGM2 supplemented (or not) with 1 µg/ml epirubicin. The 
next day, the entire supernatant was discarded, and 20 ml of 
exosome-depleted (exofree) EGM2 was added. Four T175 
flasks were used per condition. The cells were incubated in 
these conditions for 72 h, after which the exosomes were 
purified. The levels of miR-503 in the cells after the knock-
down of the genes were assessed as 24 after the addition of 
the exosome-depleted media.
Quantitative analysis of gene and microRNA 
expression by RT‑qPCR
The purification of RNA from cellular sources was per-
formed using the miRNeasy kit (Qiagen) following the 
manufacturer’s instructions. The RNA was resuspended 
in RNAse-free water and quantified by Nanodrop (Ther-
moFisher). The same kit was used to extract RNA from 
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exosomes although a modification step was added: five vol-
umes of TRIzol were added to the exosomes and the vol-
umes of chloroform and ethanol were adjusted accordingly. 
RNA was suspended in RNAse-free water and quantified 
with the Quant-it Ribogreen RNA assay kit (R11490, Ther-
moFisher) on black 96-well plates. The emitted fluorescence 
was assessed using a spectrophotometer (2030 Multilabel 
Reader VICTORTM X3 from Perkin Elmer) at 592 nm 
(emission range of fluorescein).
Two different approaches were used to measure the levels 
of different genes depending on their type. The variation 
in coding genes (gapdh, anxa2, hnRNPA2B1, thbs1, vim) 
were assessed by qRT-PCR. For that purpose, the synthe-
sis of cDNA was performed starting from 500 ng of RNA 
using the iScript Kit (BioRad) following the manufacturer’s 
instructions. The levels of mRNA in the samples were then 
assessed by qPCR using a SYBR system (Takyon, Euro-
gentec) and detected with a thermocycler (Applied Bio-
systems 7900HT, Applied Biosystems). gapdh was used as 
housekeeping gene to normalized variations in the levels 
of input RNA. For each experiment performed, two nega-
tive controls were used: a sample lacking retrotranscriptase 
enzyme (RT–) and one lacking primers. Only experiments 
with undetected gene levels for these two controls were con-
sidered. The sequences used for the design of the probes are 
in the Supplementary Methods.
For the detection of cellular non-coding RNAs (RNU44, 
RNU48, miR-503, let-7d, miR-16 miR-210, and cel-
miR-67), 3.33 ng of RNA were retrotranscribed using the 
TaqMan Reverse Transcription Kit (Applied Biosystem) 
with the TaqMan microRNA Assay (Applied Biosystems). 
The detection of the levels of these genes was performed 
using 2.2 µl of the cDNA product, 1.7 µl of TaqMan micro-
RNA assay reagent (Applied Biosystem) and a dilution of 
TaqMan Universal Master Mix (Applied Biosystem) (16.5 µl 
of enzyme diluted with 12.6 µl of RNAse free water). The 
mix was prepared prior to plating and 10 µl of solution was 
added per well. The average levels of RNU44 and RNU48 
were used to normalize RNA input in the cells. In the case of 
exosomal RNA detection, 1.67 µl of RNA extract were used 
per reaction and the normalization was performed against 
the average levels of let-7d and miR-16. Since this system of 
detection does not amplify DNA products, only the negative 
control lacking primers was prepared per experiment. In all 
cases, the level of the genes was assessed using the ΔΔCt 
method [15].
Immunofluorescence assays
HUVECs were seeded in coverslips at a density of 
2.5 × 104 cells/well and treated (or not) with epirubicin, 
from 24 to 72 h. Cells were then washed three times with 
PBS, fixed for 10 minutes with 4% paraformaldehyde 
(PFA) and then permeabilized with 70% ethanol over-
night. After permeabilization, the cells were washed 
again three times with PBS and blocked with 5% BSA for 
30 min at room temperature. Then, the cells were incu-
bated with anti-ANXA2 (1:100; #8235, Cell Signaling), 
anti-hnRNPA2B1 (1:100; #Ab6102, Abcam), anti-VIM 
(1:100; #MO72529, DAKO), and anti-TSP1 (1:100; # 
MA5-13398, Thermo Fisher) for 1 h at room temperature. 
After incubation, cells were washed three times with PBS, 
and incubated an additional 1 h with Alexa488-conjugated 
goat anti-mouse IgG (1:300; Thermo Fisher Scientific) 
and DAPI (1:500; Thermo Fisher Scientific). Then, cells 
were washed three times with PBS and once with distilled 
water. Finally, the coverslips were mounted on slides using 
Prolong (Thermo Fisher Scientific) and visualized under 
a confocal microscope (Leica SP5, Leica Microsystems, 
Wetzlar, Germany). The fluorescence intensity of hnRN-
PA2B1 staining in HUVEC cells was assessed using the 
plugin “Intensity Ratio Nuclei-Cytoplasm” on ImageJ-FIJI.
Subcellular fractionation
Endothelial cells were treated (or not) with epirubicin 
(1  µg/ml; Sigma-Aldrich, Saint-Louis, MO, USA) for 
24 h. At 24, 48, and 72 h after starting treatment, cells 
were trypsinized and pelleted by centrifugation at 1000g 
for 5 min at 4 °C. Later, the cells were washed twice with 
cold PBS and permeabilized with 0.5% PBS-Tween for 
10 min. Then, the cells were resuspended in buffer A (1 M 
Hepes pH 7.9; 1 M KCl; 1 M  MgCl2; 1 M sucrose; 10% 
glycerol; 1 M, dithiothreitol 0.01‰; Triton X-100 pro-
tease and phosphatase inhibitors (Sigma-Aldrich, Saint-
Louis, MO, USA); diethylpyrocarbonate-(DEPC) water) 
and incubated on ice for 5 min. The lysates were then 
centrifuged at 1300g for 4 min at 4 °C. The supernatant 
(S1) was recovered and centrifuged at 20,000g for 15 min 
at 4 °C. The cytosolic fraction (second supernatant, S2) 
was recovered and stored at − 20 °C. The pellet (P1) was 
washed with buffer A twice, and resuspended in buffer B 
(EDTA 100 mM pH 8; EGTA 50 mM pH 8; Dithiothréitol 
1 M; protease and phosphatase inhibitors (Sigma-Aldrich, 
Saint-Louis, MO, USA); DEPC-water). The solution was 
then incubated on ice for 30 min followed by centrifu-
gation at 1700g for 4 min (4 °C). The nuclear fraction 
present in the supernatant (S3), was recovered and stored 
at − 20 °C. The different fractions were characterized by 
western blotting using the nuclear marker Histone H3 
(#ab1791, Abcam) and the cytoplasmic marker GAPDH 
(#ab8245; Abcam). The levels of hnRNPA2B1 were 
detected by western blotting in equimolar quantities of 
protein (10 µg) from the cytoplasmic and nuclear fractions 
and quantified using ImageJ.
 J. Pérez-Boza et al.
1 3
Statistical analysis
All experiments were performed a minimum of three times 
unless otherwise stated. The plotted values represent the 
mean of the biological replicates ± the standard error of the 
mean (SEM) or the standard deviation (SD); the technique 
used is specified for each case in the figure legend. The 
statistical significance of the results was assessed using an 
unpaired t test.
Results
Characterization of exosomes and identification 
of miR‑503 binding partners
Extracellular vesicles (EVs) were purified using ultracentrif-
ugation and characterized by western blotting detecting the 
following exosomal (CD63, CD9, CD81, and syntenin) and 
cellular markers (mitochondrial cytochrome C) (Fig. 1a). 
Dynamic light scattering revealed vesicles with an aver-
age size of 100 nm (Fig. 1b), suggesting an enrichment of 
exosomes in our preparation. Electronic microscopy analysis 
confirms the size as well as the presence of the tetraspanin 
CD63 and the endothelial marker CD105 (Fig. 1c).
As previously shown [9], epirubicin increases the export 
of miR-503 into exosomes in human umbilical vein endothe-
lial cells (HUVECs) (Fig. 1d). To identify the binding part-
ners of miR-503 we transfected HUVECs with a synthetic 
miR-503-biotin. We then determined if the biotinylation 
of miR-503 interfered with the mechanism of export trig-
gered by epirubicin by assessing the levels of miR-503 in 
exosomes after treatment (Supplementary Fig. S2a). We 
found little to no effect linked to the presence of a biotin tag 
in the selective export of miR-503 in response to epirubicin, 
ranging around the twofold increase in native conditions 
(Fig. 1d) and after miR-503 biotin transfection (Fig S2a).
To identify the miR-503 binding partners, we transfected 
HUVECs with the biotin-microRNA construct and followed 
a double crosslinking strategy (Fig. 1e): first, by inducing the 
formation of RNA–protein bonds and, second, by stabilizing 
protein–protein interactions. Following this methodology, 
we pulled down the microRNA and identified its binding 
protein partners by mass spectrometry. The efficiency of the 
transfection of miR-503-Biotin was assessed by qPCR on 
cellular lysates (Fig S2b).
A total of nine different proteins were identified by mass 
spectrometry: propionyl-CoA carboxylase alpha subunit 
(PCCA), pyruvate carboxylase (PC), heparan sulfate pro-
teoglycan 2 (Perlecan), fibronectin 1 (FN1), thrombospon-
din-1 (TSP1), β-actin (ACTB), vimentin (VIM), annexin A2 
(ANXA2), and heterogeneous nuclear ribonucleoprotein A2/
B1 (hnRNPA2B1). A brief description of their main roles 
in the cell is summarized in Supplementary Table 1. Both 
PCCA and PC are binders of endogenous biotin, hence their 
identification [16]; they were not considered for further anal-
ysis. Perlecan, TSP1 and FN1 are part of the extracellular 
matrix [17–19], while ACTB and VIM are main components 
of the cytoskeleton and regulate motility, cellular stability, 
and cellular division [20, 21]. ANXA2, via its involvement 
in cellular transduction, can modulate cellular growth and 
various signaling processes. In addition, it was also recently 
discovered that ANXA2 can bind to mRNAs [22–24] and 
mediate the exosomal export of microRNAs. The most well-
known function of hnRNPA2B1 is shuttling mRNA from the 
nucleus to the cytoplasm and regulating post-transcriptional 
gene expression [25]. Interestingly, hnRNPA2B1 can also 
bind microRNAs with a specific sequence and promote their 
export into exosomes [26].
The microRNA-protein association between miR-503 and 
its putative partners was then validated by western blotting 
with the proteins of interest in the biotinylated-miR-503 
pull-down fraction. Figure 1f shows that, ACTB and Perle-
can were not found in association with miR-503-botin while 
FN1, TSP1, hnRNPA2B1 and, to a lesser extent, VIM and 
ANXA2, were enriched in the pull-down fraction.
To mitigate bias associated with the unspecific detec-
tion of proteins, we transfected HUVECs with a c. elegans 
microRNA carrying a biotin tag (cel-miR-67-biotin). The 
efficiency of the transfection is shown in Figure S2c and the 
effect of Epi on the exosomal export of cel-miR-67 in Fig 
S2d. Then, we pulled down the microRNA and detected by 
western blot, the proteins previously validated. Our results 
(Fig. 1f) pointed to FN1 as a non-specific contaminant of our 
pull-down and was excluded from further analysis.
The putative complex formed by miR-503 in combination 
with ANXA2, hnRNPA2B1, TSP1, and VIM will be referred 
to in the following sections as the MicroRNA Exporting 
Complex or MEC.
Epirubicin does not regulate the expression 
of the MEC components
To study whether epirubicin regulates the expression of 
some of the components of the MEC in HUVECs, we 
assessed the mRNA and protein abundance in cells after 
treatment. As shown in Fig. 2a, epirubicin reduces the 
expression of thbs1 and hnRNPA2B1. Interestingly, the 
regulation is only significant 24 h after treating the cells 
with epirubicin. At protein level (Fig. 2b, c), we observe 
that epirubicin has little effect on the protein abundance of 
the MEC components: while changes in the abundance of 
ANXA2 and TSP1 follow a similar trend to the changes 
observed at RNA level, the effect is too modest to be sig-
nificant. These results suggest that epirubicin does not affect 
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the export of miR-503 by regulating the abundance of the 
MEC components.
The exosomal export of ANXA2 is regulated 
by epirubicin
To determine if miR-503 is co-exported with all or some 
of the components of the MEC, we treated HUVECs with 
epirubicin and then collected the exosomes produced 
during the following 72 h. With the exception of VIM, 
all MEC proteins were detected in exosomes (Fig. 2d). 
Interestingly, only ANXA2 showed a strong enrichment 
(average 8-fold) in exosomes after the treatment with 
epirubicin. Taken together, these results suggest that the 
MEC is, at least, partially destabilized upon epirubicin 
treatment.
Fig. 1  Exosome characterization and identification of miR-503 
binding proteins: a exosome characterization of HUVEC lysates 
and exosomes (10 µg) against the EV markers: CD9, CD63, CD81, 
syntenin (SYN), and the cellular marker cytochrome C (Cyt C). b 
Dynamic light scattering analysis of exosomal preparations. c Elec-
tron microscopy images of HUVEC exosomes labeled with anti-
CD63 and anti-CD105, scale bars = 100 nm. d Cells were treated with 
epirubicin for 24  h. Cell lysates were prepared 24  h after treatment 
and exosomes were collected 72 h after removing the chemotherapeu-
tic drug. Cellular and exosomal levels of miR-503 were evaluated by 
qPCR. Data show mean ± SEM (n = 3). **p < 0.01 vs. respective con-
trol. e Schematic representation of the protocol used to identify the 
MEC proteins. HUVECs (30 × 106 cells) were transfected with miR-
503-biotin (10  nM). The following day, the cells were crosslinked 
with DTSSP and UV. HUVECs lysates were incubated with strepta-
vidin beads. Both input (IN) (cellular lysate) and pull-down fractions 
(PD) were separated by SDS-PAGE. Isolated proteins were identi-
fied by mass spectrometry and f validated by western blotting against 
pull-down (PD) and input (IN) (1% of cell lysate) fractions using vin-
culin as loading control. Cel-miR-67 was used as a negative control 
for the pull-down
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ANXA2 and miR‑503 present the most stable 
interaction among the MEC components
To study the composition of the MEC, we decided to pull 
down miR-503 prior any crosslinking and after only induc-
ing the formation of protein–RNA bonds with UV crosslink-
ing. Theoretically, the strongest interaction between the 
components of the MEC and the microRNA should be main-
tained in non-crosslinked conditions while the weakest inter-
actions would only be detected when both UV and chemical 
crosslinkings were performed. Our results (Fig. 3a) suggest 
that in the absence of crosslinking, ANXA2 is the most 
abundant MEC protein present in the pull-down. To a much 
lesser extent, VIM can also be detected in non-crosslinked 
conditions. Interestingly, both TSP1 and hnRNPA2B1 can 
only be detected when both crosslinkings are performed.
Epirubicin disrupts the interaction between miR‑503 
and hnRNPA2B1 and VIM
We then assessed if the interaction between miR-503 and 
the MEC components was affected by epirubicin treatment. 
For that purpose, the components of the MEC were immu-
noprecipitated and the levels of miR-503 determined by 
qPCR. As shown in Fig. 3b, in untreated conditions, miR-
503 was coprecipitated with all MEC components, although 
the levels bound to ANXA2 were minimal. Interestingly, 
hnRNPA2B1 showed very high affinity for miR-503 (10, 36, 
and 79-fold change when compared to the cellular lysate).To 
study if the interaction between the components of the MEC 
and miR-503 was affected by the chemotherapeutic drug, we 
treated endothelial cells with epirubicin and measured the 
levels of miR-503 in the immunoprecipitates before and after 
treatment (Fig. 3c). In the cases of VIM, and hnRNPA2B1 a 
significant reduction of miR-503 in the immunoprecipitates 
was observed after treatment (p = 0.025 and p = 0.00003, 
respectively). Strikingly, the opposite effect was observed for 
ANXA2 (~ 2.3-fold increase, p = 0.019). In addition, when 
using the transfection of cel-miR-67 as a negative control 
(Fig S3a and S3b), we observed that epirubicin does not 
have any effect on the interaction between these proteins 
and the exogenous RNA. In combination, these results sug-
gest that epirubicin modulates the interaction between miR-
503 and some components of the MEC (ANXA2, VIM, and 
hnRNPA2B1).
Epirubicin treatment promotes the relocation 
of hnRNPA2B1 into the nucleus
Aiming to assess whether the changes in affinity between 
MEC components and miR-503 were associated to fluctua-
tions in protein distribution, we decided to study the effect 
of epirubicin on protein localization. Confocal analysis 
Fig. 2  Epirubicin regulates the mRNA levels of TSP1 and hnRN-
PA2B1. HUVECs were treated with epirubicin for 24 h and the lev-
els of a RNA and b proteins were assessed, respectively, by qPCR 
at 24, 48, and 72 h after treatment and western blotting at 24, 48, 72, 
and 96  h after treatment. Data represents fold change against non-
treated cells. Plots show mean and SEM from three independent 
experiments. *p < 0.05, ***p < 0.001. c Representative western blot. 
d HUVECs were treated with epirubicin for 24 h and exosomes were 
produced for additional 72 h. Exosomes were purified by ultracentrif-
ugation and the levels of proteins were determined by western blot-
ting (10 µg/lane). Representative example of N = 3
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revealed that, in untreated conditions, hnRNPA2B1 is mainly 
located in the nucleus and in some cytoplasmic granules 
(Fig. 4a, b). Interestingly, epirubicin treatment promotes 
the relocation of hnRNPA2B1 into the nucleus 24 and 48 h 
after treatment. This migration was not observed for any 
of the other MEC components (Fig S4a). The relocation of 
hnRNPA2B1 was confirmed by western blotting analysis of 
subcellular fractions (validation of the technique in Supple-
mentary Fig. S4b) showing an increase in the ratio between 
cytoplasmic and nuclear abundance at 24 and 48 h that is 
partially reverted at 72 h (Fig. 4c, d).
ANXA2 and hnRNPA2B1 are key mediators 
of the exosomal export of miR‑503
To study the role of the MEC components in the export of 
miR-503, we used a dual approach. First, we studied if the 
abundance of the components of the MEC could determine 
the fate of miR-503 or miR-210, a microRNA-control pre-
sent in the cell at similar concentrations than miR-503. For 
that purpose, we knocked down the putative partners of the 
microRNA (validation of siRNA knock-down Figure S5) and 
assessed the exosomal export of the microRNAs. Our results 
(Fig. 5a) suggest that the knock-down of thbs1 reduces sig-
nificantly the export of miR-503, although the level by which 
is reduced is minimal (fold change 0.8). Interestingly, both 
the knock-down of ANXA2 and hnRNPA2B1 increased the 
export of miR-503. While lower levels of ANXA2 induce 
a 1.5-fold increase, slightly below the increase observed 
upon epirubicin treatment in non-transfected conditions, the 
knock-down of hnRNPA2B1 reproduced the effect of the 
chemotherapeutic drug to the same levels (ranging in two- to 
three-fold change increase). No significant differences were 
observed for the knock-down of vim in untreated conditions 
and none of the MEC protein knock-downs affected signifi-
cantly the export of miR-210 (Fig. 5b).
Second, we studied whether the knock-down of the MEC 
proteins could affect the incorporation of miR-503 into 
exosomes triggered by the treatment with epirubicin. For 
that purpose, cells transfected with siRNA against the com-
ponents of the MEC (or siScramble) were treated with epi-
rubicin and the levels of exosomal miR-503 were assessed. 
Our results show that, the knock-down of any of the com-
ponents of the MEC reduced the exosomal encapsulation of 
miR-503 upon epirubicin treatment (Fig. 5c). Interestingly, 
the knock-down of both ANXA2 and hnRNPA2B1 had the 
most dramatic effect on the exosomal encapsulation of miR-
503. While no effect was observed in untreated conditions, 
epirubicin seemed to reduce the exosomal export of miR-210 
in most conditions, although when compared to siScr, none 
of the knock-downs had any effect (Fig. 5d).
Finally, we determined whether the changes observed 
in the exosomal microRNA profiles were a reflection 
of changes in the cellular levels of miR-503, or the 
Fig. 3  Epirubicin disrupts the interaction between miR-503 and 
VIM and hnRNPA2B1. a HUVECs (30·106 cells) were transfected 
with miR-503-biotin (10  nM). The following day, the cells were 
crosslinked with DTSSP and UV (UV + CHL), only UV (UV) or not 
subjected to any crosslinking (No CL). HUVECs lysates were incu-
bated with streptavidin beads. Both input (IN) (cellular lysate) and 
pull-down fractions (PD) were separated by SDS-PAGE and revealed 
by western blotting using indicated proteins. Input (IN) = 1% of cell 
lysate. Vinculin was used as loading control. b, c HUVECs were 
transfected with miR-503 (10  nM). 48  h later, immunoprecipita-
tion assays were performed using the indicated antibodies or an IgG 
control and the levels of miR-503 were evaluated by qPCR. Plots 
show b fold change of miR-503 in the immunoprecipitated (IP) vs 
input fractions (IN) in non-treated cells and c fold change of immu-
noprecipitated miR-503 in epirubicin-treated (EPI) vs non-treated 
cells (NT). Plots represent mean and SEM from three independent 
experiments,*p < 0.05; **p < 0.01, ***p < 0.001. IN = 1% of the cel-
lular lysate before immunoprecipitation
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consequence of a specific export mechanism (Fig. 5e). The 
knock-down of any of the components of the MEC failed 
to increase the cellular production of miR-503. Only when 
hnRNPA2B1 was knocked down we observed a modest, 
but significant reduction in the cellular levels of miR-503. 
In the case of miR-210 (Fig. 5f), any treatment of the cells 
with either siRNA or epirubicin induced the production of 
reduced levels of this microRNA.
The mecanism of exosomal export of miR‑503 
is conserved in microvascular cells
To validate our findings, we confirmed our results in human 
microvascular endothelial cells (HMVECs), presenting a 
closer phenotype to cells located in the tumor microenviron-
ment. First, we assessed whether epirubicin also induced the 
exosomal export of miR-503. For that purpose, we isolated 
Fig. 4  hnRNPA2B1 re-localizes into the nucleus after epirubicin 
treatment. a Confocal images of hnRNPA2B1 (green) and DAPI 
(blue) of HUVECs treated with epirubicin for 24  h. Pictures taken 
at the indicated times after starting the treatment. b Quantification 
of the intensity in the cytoplasm and nucleus were performed using 
ImageJ on epifluorescence images. c Nuclear and cytoplasmic frac-
tions from HUVECs treated with epirubicin and analysed by western 
blotting for hnRNPA2B1 localization. d Abundance ratio of hnRN-
PA2B1 between nucleus and cytoplasm in subcellular fractions. All 
plots show results from three independent experiments. *p < 0.05. 
Validation of subcellular fractionation method in Supplementary Fig-
ure S4
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HMVEC exosomes from epirubicin-treated or untreated 
cells. Our findings suggest (Fig. 6a) that the treatment with 
the chemotherapeutic drug also induces miR-503 sorting 
into exosomes. Then, we determined if miR-503 also inter-
acted with the same MEC partners in HMVEC. Our results 
showed (Fig. 6b) that, after pulling down miR-503-biotin, 
we could detect two of the previously identified MEC 
components (ANXA2 and hnRNPA2B1) while TSP1 and 
VIM were not detected.
To study if epirubicin also affects the interaction between 
miR-503 and some components of the MEC in HMVECs, we 
treated these cells with epirubicin and then immunoprecipi-
tated the proteins of interest. Our results show that, both in 
untreated conditions (Fig. 6c) and after treatment (Fig. 6d), 
Fig. 5  ANXA2, hnRNPA2B1, 
TSP1 and VIM are necessary 
for the effect of epirubicin on 
the exosomal export of miR-
503. HUVECs were transfected 
with siRNA for the indicated 
protein or control siRNA (siScr) 
(20 nM). Then, cells were 
treated with epirubicin for 24 h 
(or not) and exosomes were 
produced for the following 72 h. 
The levels of miR-503 (a, c, e) 
and miR-210 (b, d, f) in purified 
cells and exosomes were then 
assessed via qPCR. Data show 
fold change of miR-503 (a) 
and miR-210 (b) in exosomes 
from siRNA-transfected cells 
vs Scramble RNA-transfected 
(siScr) cells in non-treated 
conditions. Fold change of miR-
503 and mR-210 respectively 
in exosomes (c, d) and cells (e, 
f) after siRNA transfection and 
epirubicin treatment normal-
ized to untreated conditions. 
Plots show mean and SEM 
of three independent experi-
ments. (*p < 0.05; **p < 0.01, 
***p < 0.001)
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the interaction between miR-503 and the MEC components 
follows the same trends observed for HUVECs: before treat-
ment, the levels of ANXA2 binding miR-503 are low while 
the opposite is observed for hnRNPA2B1 (Fig. 6c). After 
treatment, these interactions are reversed and increased miR-
503 is found in the immunoprecipitated ANXA2 while less 
microRNA is associated to hnRNPA2B1 (Fig. 6d).
Discussion
In previous work we showed that the treatment with the 
chemotherapeutic agent epirubicin induces the over export 
of the anti-tumoral miRNA-503 in endothelial cells. These 
results suggested the presence of a specific mechanism 
behind the sorting of this microRNA. Unfortunately, little is 
known about the machinery regulating the exosomal export 
of microRNAs. Only a few studies have reported the role 
of RNA-binding proteins in promoting the export of some 
subclasses of microRNAs (hnRNPA2B1 [26], Syncrip [27], 
MVP [28], MEX3C [29] and Y-Box [30]). Surprisingly, in 
this study we show that the exosomal sorting of miR-503 is 
negatively regulated by its binding to hnRNPA2B1. This is 
the first evidence showing that RBPs can bind and prevent 
the export of miRNAs into exosomes.
The proteomic analysis of the binding partners of miR-
503 revealed nine potential proteins possibly involved in 
exosomal miR-503 export. Leaving aside the two proteins 
identified as natural biotin binders, one protein identified as 
a non-specific contaminant and those not validated by west-
ern blotting, the identified partners of miR-503 were TSP1, 
VIM, ANXA2, and hnRNPA2B1.
While no relationship has been established between TSP1 
and the binding or export of RNAs, thrombospondin-1 has 
often been studied in the extracellular compartment. This 
protein is underrepresented in exosomes derived from naso-
pharyngeal carcinoma cells [31] and in EVs derived from 
cells undergoing epithelial to mesenchymal transition (EMT) 
[32]. Despite this, most of the publications studying circu-
lating TSP1 have focused on its role in angiogenesis [33, 
34] and as a marker of EMT [35]. Our results propose an 
ambiguous role for TSP1 in the MEC: the knock-down of 
this protein suggests that TSP1 has a modest, but significant 
effect in the exosomal export of miR-503 independently of 
the treatment with epirubicin. However, no significant differ-
ences were observed when the interaction between TSP1 and 
miR-503 was studied. These results suggest that TSP1 may 
be involved in the interaction between secondary partners 
of the MEC and the microRNA export machinery, but not 
directly binding the microRNA and regulating its export.
Our study suggests that VIM could be involved in the 
export of miR-503: in cells with reduced VIM abundance, 
epirubicin fails to promote the exosomal export of miR-503. 
Given that in untreated conditions the knock-down of this 
protein does not have any significant effect, it is possible that 
VIM regulates the localization of the MEC before the release 
Fig. 6  ANXA2 and hnRNPA2B1 are necessary for the effect of epi-
rubicin on the exosomal export of miR-503 in microvascular endothe-
lial cells. HMVECs were treated with epirubicin for 24 h. Cell lysates 
were prepared 24 h after treatment and exosomes were collected 72 h 
after removing the chemotherapeutic drug. Cellular and exosomal 
levels of miR-503 were evaluated by qPCR. Plot represents mean 
and SEM (n = 3). b HMVECs were transfected with miR-503-biotin 
(10 nM). The following day, the cells were crosslinked with DTSSP 
and UV. HMECs lysates were incubated with streptavidin beads. Both 
input (IN) (cellular lysate) and pull-down fractions (PD) were sepa-
rated by SDS-PAGE. Previously identified components of the MEC 
complex were validated by western blotting against pull-down (PD) 
and input (IN) (1% of cell lysate) fractions using vinculin as loading 
control. c HMVECs were transfected with miR-503 (10  nM). 48  h 
later, immunoprecipitation assays were performed using the indicated 
antibodies and the levels of miR-503 were evaluated by qPCR. Plot 
shows fold change of miR-503 in the immunoprecipitated (IP) vs 
input fractions (IN) in non-treated cells and (d) fold change of immu-
noprecipitated miR-503 in epirubicin-treated (EPI) vs non-treated 
cells (NT). Plots represent mean and SEM from three independent 
experiments, *p < 0.05, **p < 0.01, ***p < 0.001. IN = 1% of the cel-
lular lysate before immunoprecipitation
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of miR-503 for exosomal encapsulation. This hypothesis is 
supported by two factors: first, this protein was mostly pulled 
down after inducing the formation of protein–protein bonds. 
Second, by the physiological role of VIM in the cell: vimen-
tin regulates the reorganization of the cellular cytoskeleton 
and the rearrangement of extracellular adhesion molecules 
[36]. Several publications have also found that VIM can be 
encapsulated into exosomes and that the levels at which it 
can be found often correlate with aggressiveness in the par-
ent cells [37]. Unfortunately, in the cellular model used in 
this study, we could not detect this protein in the extracel-
lular fraction. In addition, VIM was recently found to bind 
RNAs: VIM can stabilize collagen mRNA by binding to a 
stem loop region found at the 5′UTR [38]. After this study, 
it has been repeatedly showed that VIM can stabilize several 
other mRNAs following the same mechanism: alkaline phos-
phatase mRNA [39], mu-opioid receptor [40], and eIF2α 
[41]. Even though our experiments failed to prove direct 
binding between VIM and miR-503, we show that epiru-
bicin can disrupt the interaction between these partners and 
propose a role for VIM during microRNA exosomal export.
ANXA2 is one of the top 20 most common proteins 
found in exosomes [42] and mediates EV uptake via the 
immobilization of the vesicles to the surface of the recipient 
cells [43]. At the cellular level, ANXA2 has been associ-
ated with exo- and endocytosis, as well as with the traffick-
ing of membranous bodies, lipid raft formation, and signal 
transduction (reviewed in Ref. [44]). Moreover, ANXA2 
can induce EMT by increasing the migration and invasion 
capacities of cancer cells [45], reducing apoptosis and medi-
ating multi-drug resistance [46]. At the extracellular level, 
ANXA2 can induce pro-angiogenic processes and metastatic 
phenotypic switch by promoting cellular motility [47–49]. 
Regarding RNA, some studies have found that ANXA2 can 
bind some mRNAs such as c-myc [50] and “infectious bron-
chitis virus pseudoknot” RNA [51]. Additionally, another 
recently published study shows that some proteins of the 
same calcium-biding signaling family regulate the export 
of exosomal microRNAs. Although promising, these results 
showed that ANXA2 only participates in the encapsulation 
of six specific microRNAs without shared motifs [52] (none 
of them is miR-503). According to our results, ANXA2 has 
an affinity for miR-503 stable enough that it is pulled down 
without any sort of crosslinking. These results, in combina-
tion with previous evidence showing that ANXA2 can bind 
RNA suggest that ANXA2 is the main protein in the MEC 
directly interacting with miR-503. Although the treatment 
with epirubicin only increases modestly but not signifi-
cantly the levels of cellular ANXA2, its exosomal export 
is increased by eightfold. Even though the relative quantity 
of ANXA2 binding to miR-503 under untreated conditions 
is very low, likely due to the high abundance of this protein 
in the cell, the treatment with epirubicin strongly increases 
the pull-down of miR-503-bound ANXA2 (2.5-fold). This 
switch could indicate that either epirubicin induces the bind-
ing of ANXA2 to the microRNA promoting its exosomal 
export or that epitopes unavailable for IP are revealed upon 
treatment. Since in untreated conditions, ANXA2 already 
shows a strong interaction with miR-503, our results sup-
port the latter hypothesis. At the same time, given that 
reduced levels of ANXA2 promote the export of miR-503 
in untreated conditions but impair the export induced by epi-
rubicin, our results point to a crucial role for ANXA2 in the 
microRNA export mechanism triggered by chemotherapy.
The second component of the MEC, key in the export of 
miR-503 into exosomes is hnRNPA2B1. The known roles 
of hnRNPA2B1 include DNA replication and repair, RNA 
nuclear export, pre-mRNA splicing, mRNA stability [25], 
pri-miRNA processing and mediation of splicing events 
[53], among others. In addition, hnRNPA2B1 can also bind 
to lncRNAs and regulates the expression of some genes at 
post-transcriptional level [54]. Several studies have also 
focused on the role of this protein in disease. In hepatocel-
lular carcinoma, hnRNPA2B1 can act as an oncogene via the 
control of alternative splicing processes [55] and induction 
of EMT [56]. Moreover, hnRNAP2B1 has been found to be a 
circulating biomarker of lung cancer [57] and a dual media-
tor of the development of breast cancer. First, hnRNPA2B1 
is associated with the loss of breast cancer susceptibility 
gene 1 (brca1) [58] and, second, by being a regulator of the 
STAT3-ERK1/2-signaling pathway [59]. hnRNPA2B1 has 
also been linked to the efficiency of chemotherapy in vitro: 
Inhibition of hnRNPA2B1 expression improved chemosensi-
tivity to gemcitabine, 5-fluorouracil (5-FU), and oxaliplatin 
in pancreatic cancer cell lines [60].
Regarding exosomal RNA loading, hnRNPA2B1 was 
the first RBP known to regulate the export of microRNAs. 
In their study, Villarroya et al. discovered that this protein 
binds to microRNAs with a specific motif and promotes their 
exosomal export upon sumoylation [26]. Interestingly, miR-
503 does not have the “exo-motif” described in this study, 
likely suggesting that the involvement of hnRNPA2B1 in the 
export of this microRNA does not follow the same mecha-
nism. Moreover, unlike in their study, we did not observe 
any differences in the sumoylation of hnRNPA2B1 between 
cells and exosomes, likely due to differences in the cellular 
model used. Another recent study showed that hnRNPA2B1 
can bind the host gene of miR-503 [61]. Their results suggest 
that the binding region of this RBP falls outside the coordi-
nates of the mature miR-503, thus supporting the hypothesis 
that hnRNPA2B1 does not directly bind to miR-503. Our 
data showed that hnRNPA2B1 can only be identified along 
with miR-503 when both protein–protein and protein–UV 
crosslinking is induced. These results propose the hypothesis 
that hnRNPA2B1 does not bind directly to miR-503, but to 
other components of the MEC. Our findings also point to 
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hnRNPA2B1 having high affinity for miR-503 (avg 40-fold) 
and that, upon epirubicin treatment, this affinity is strongly 
reduced. At the same time, we have shown that epirubicin 
induces the relocation of cytoplasmic hnRNPA2B1 towards 
the nucleus. Interestingly, reduced levels of hnRNPA2B1 
also promote the export of exosomal miR-503 to the same 
levels observed by the treatment with epirubicin alone 
(~ 2.5-fold).
The combination of these results suggests that epirubicin 
induces the increased exosomal export of miR-503 by dis-
rupting the interaction between hnRNPA2B1 and miR-503/
ANXA2. Then, hnRNPA2B1 is relocated into the nucleus 
and a fraction of the initial MEC, composed by ANXA2 
binding to miR-503, is sorted into exosomes. Our findings 
suggest that ANXA2 mediates the interaction between 
miR-503 and hnRNPA2B1. These results are supported by 
the evidence showing that when the levels of ANXA2 are 
reduced (by siRNA), epirubicin cannot promote the over 
export of miR-503 because hnRNPA2B1 is no longer asso-
ciated to this microRNA. The validation of our results in 
HMVECs proves the conservation of a miR-503/ANXA2/
hnRNPA2B1 axis across different subtypes of endothelial 
cells thus supporting the role of both RBPs in mediating 
the export of microRNAs. Given that hnRNPA2B1 medi-
ates repair processes at sites of DNA double-strand break 
(DBS) hotspots [62], we hypothesize that the relocation of 
hnRNPA2B1 towards the nucleus upon epirubicin treat-
ment could respond to a recycling mechanism initiated by 
the DNA destabilization triggered by the chemotherapeutic 
drug. Whether this relocation is the cause of the MEC desta-
bilization or its consequence, remains unknown. Although 
several independent studies [26, 27] have found a series of 
RBPs that can bind and promote the export of microRNAs, 
this study is the first one to propose a mechanism by which 
proteins can promote cellular retention and inhibit the exo-
somal export of a specific microRNA.
Supplementary methods The parameters used for the mass 
spectrometry analysis, the quantification of immunofluores-
cence, the primer sequences, and the conditions used for the 
detection of the potential components of the MEC are all 
explained in detail in the Supplementary Methods.
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